Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Single-group study (n=12) of a single oral psilocybin dose (20–25 mg, weight-based) assessing synaptotrophic effects with pre/post [11C]-UCB-J PET and fMRI in detoxified individuals with opioid use disorder (OUD).
Details
Single-center, single-group (n=12) study at Yale evaluating synaptic density changes after a single oral psilocybin dose with paired [11C]-UCB-J PET and resting-state fMRI pre- and 1-2 weeks post-dosing.
Participants are medically healthy, detoxified inpatients with opioid use disorder who receive inpatient detoxification, baseline PET, psilocybin administration (20 mg if <70 kg; 25 mg if ≥70 kg), overnight observation and may be discharged the day after dosing with outpatient urine toxicology twice weekly prior to the second PET.
Outcomes include changes in [11C]-UCB-J PET measures of synaptic density, resting-state connectivity on fMRI, and exploratory behavioural correlations; imaging performed at the Yale PET Center with anatomical MRI for registration and partial volume correction.